{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:39:38Z","timestamp":1786984778027,"version":"build-2736575974"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"am","delay-in-days":259,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.arcmed.2024.103083","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T14:51:28Z","timestamp":1726584688000},"page":"103083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preliminary Efficacy and Safety Analysis of Tafamidis in Post-Liver Transplant Patients with Hereditary Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-2052","authenticated-orcid":false,"given":"Takahiro","family":"Okumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-4599","authenticated-orcid":false,"given":"Kenji","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-7037","authenticated-orcid":false,"given":"Hiroaki","family":"Hiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2024.103083_bib0001","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arcmed.2024.103083_bib0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40119-021-00222-w","article-title":"Multidisciplinary approaches for transthyretin amyloidosis","volume":"10","author":"Koike","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.arcmed.2024.103083_bib0003","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2169\/internalmedicine.47.1399","article-title":"Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation","volume":"47","author":"Okamoto","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.arcmed.2024.103083_bib0004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","article-title":"Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients","volume":"7","author":"Yazaki","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.arcmed.2024.103083_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1253\/circj.CJ-19-1044","article-title":"Advantages and emerging problems of novel treatments for transthyretin cardiac amyloidosis","volume":"84","author":"Okumura","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.arcmed.2024.103083_bib0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.arcmed.2024.103083_bib0007","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3988\/jcn.2017.13.4.444","article-title":"Tafamidis for a transplant patient with transthyretin amyloid polyneuropathy","volume":"13","author":"Romero-Imbroda","year":"2017","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.arcmed.2024.103083_bib0008","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/13506129.2015.1031373","article-title":"Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report","volume":"22","author":"Kon","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.arcmed.2024.103083_bib0009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","article-title":"Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy","volume":"63","author":"Koike","year":"2004","journal-title":"Neurology"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T16:29:39Z","timestamp":1737563379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440924001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0188440924001358"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103083","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary Efficacy and Safety Analysis of Tafamidis in Post-Liver Transplant Patients with Hereditary Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103083"}}